ArticleMolecular and clinical oncology2017

A retrospective study of docetaxel and bevacizumab as a second- or later-line chemotherapy for non-small cell lung cancer.

Koichi Kurishima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.